HIV drug resistance testing is becoming an integral part of antiretroviral drug development and of patient management. The parameters that characterize the performance of both phenotypic and genotypic assays and the validation of this performance are essential to their proper use for these applications. Several principles and biological factors impacting drug resistance testing are summarized. Considerations regarding quality control and validation of the performance of genotypic and phenotypic assays are also addressed.
References
1.
HirschM.S., ConwayB., D'AquilaR.T., JohnsonV.A., Brun-VézinetF., ClotetB., DemeterL.M., HammerS.M., JacobsenD.M., KuritzkesD.R., LovedayC., MellorsJ.W., VellaS., & RichmanD.D.Antiretroviral drug resistance testing in adults with HIV infection. Journal of the American Medical Association1998; 279: 1984–1991.
2.
GünthardH.F., WongJ.K., HavlirD.V., & RichmanD.D.Comparative performance of high-density oligonucleotide sequencing and dideoxynucleotide sequencing of HIV type 1 pol from clinical samples. AIDS Research in Human Retrovirus1998; 14: 869–876.
3.
DeGruttolaV., DixL., D'AquilaR., HolderD., PhillipsA., Ait-KhaledM., BaxterJ., ClevenberghP., HammerS., HarriganR., KatzensteinD., LanierR., MillerM., ParaM., YerlyS., ZolopaA., MurrayJ., PatickA., MillerV., CastilloS., PedneaultL., & MellorsJ.The relationship between baseline HIV drug resistance and response to antiretroviral therapy: re-analysis of retrospective and prospective studies using a standardized data analysis plan. Antiviral Therapy2000; 5: 41–48.
4.
HavlirD.V., EastmanS., GamstA., & RichmanD.D.Nevirapine-resistant human immunodeficiency virus: kinetics of replication and estimated prevalence in untreated patients. Journal of Virology1996; 70: 7894–7899.
5.
StuyverL., WyseurA., RomboutA., LouwagieJ., ScarcezT., VerhofstedeC., RimlandD., SchinaziR.F., & RossauR.Line probe assay for rapid detection of drug-selected mutations in the human immunodeficiency virus type 1 reverse transcriptase gene. Antimicrobial Agents and Chemotherapy1997; 41: 284–291.
6.
SchuurmanR., DemeterL., ReichelderferP., TijnagelJ., de GrootT., & BoucherC.Worldwide evaluation of DNA sequencing approaches for identification of drug resistance mutations in the human immunodeficiency virus Type 1 reverse transcriptase. Journal of Clinical Microbiology1999; 37: 2291–2296.
7.
SchuurmanR., BrambillaD., de GrootT., & BoucherCSecond worldwide evaluation of HIV-1 drug resistance genotyping quality using the ENVA 2 panel. [Abstract 58.] Antiviral Therapy1999; 4 (Suppl. 1): 41.
8.
HertogsK., ZolopaA.R., BloorS., SchaferB., De VroeyV., WarfordA., LarderB., & MeriganT.A blinded comparative analysis of two genotyping service laboratories: full sequence analysis of HIV-1 protease and reverse transcriptase. [Abstract 87.] Antiviral Therapy1999; 4 (Suppl. 1): 59.
9.
RichmanD.D., JohnsonV.A., MayersD.L., ShirasakaT., O'BrienM.C., & MitsuyaH.In vitro evaluation of experimental agents for anti-HIV activity. In: Current Protocols in Immunology, 1993 Suppl. 8, Unit 12.9, pp. 1–21. Edited by ColiganJ.E., KruisbeekAm, MarguliesD.H., ShevachE.M., & StroberW.Brooklyn, NY: John Wiley & Sons Inc.
10.
LanierR., DanehowerS., DalugeS., CutrellA., TisdaleM., PearceG., SpreenB., LafonS., KempS.D., BloorS., & LarderB.A.Genotypic and phenotypic correlates of response to abacavir (ABC, 1592). [Abstract 52.] Antiviral Therapy1998; 3 (Suppl. 1): 36.
11.
MillerM.D., WulfsohnM.S., MargotN.A., CoakleyD.F., BrosgartC.S., PetropoulosC.J., & HellmanN.S.Retrospective analysis of baseline susceptibility to adefovir dipivoxil is predictive of virological response in GS-96-408. [Abstract 106.] Antiviral Therapy1999; 4 (Suppl. 1): 70.
12.
de BethuneM.P., HertogsK., HeyndrickxL., VingerhoetsJ., FransenK., AzijnH., MichielsL., JanssensW., ScholliersA., LarderB., BloorS., PauwelsR., & van der GroenG.Does natural or acquired resistance to reverse transcriptase and protease inhibitors, observed in HIV-1 groups M (subtypes A–H) and [O], differ from subtype B? [Abstract 49.]Antiviral Therapy1999; 4 (Suppl. 1): 33.
13.
LittleS.J., DaarE.S., D'AquilaR.T., KeiserP.H., ConnickE., WhitcombJ.M., HellmannN.S., PetropoulosC.J., PittJ.A., RosenbergE.S., KoupR.A., & RichmanD.D.The spectrum and frequency of reduced antiretroviral drug susceptibility with primary HIV infection in the United States. Journal of the American Medical Association1999; 282: 1142–1149.
14.
Leigh BrownA.J., PreciousH.M., WhitcombJ., DaarE., D'AquilaR.T., KeiserP., ConnickE., HellmannN., PetropoulosC., WongJ.K., RichmanD.D., & LittleS.J.Novel amino acid change influencing susceptibility to nevirapine detected in primary HIV infection. 7th Conference on Retroviruses and Opportunistic Infection. San Francisco, CA, January 30–February 2, 2000.
15.
D'AquilaR.T.Limits of resistance testing. Antiviral Therapy2000; 5: 71–76.
